Good day, everyone, welcome to the Amesite Inc. annual meeting. I'll turn the call over to your host, Dr. Ann Marie Sastry, CEO and Founder. Good morning, welcome to the 2026 annual stockholders meeting of Amesite Inc. My name is Dr. Ann Marie Sastry, Founder and CEO. It's my pleasure to welcome you here today for the meeting. We're excited to be hosting our virtual meeting, which allows us to be more inclusive and reach a greater number of our stockholders. We have stockholders attending via the web portal. As is our custom, we'll conduct the business portion of our meeting first and answer questions at the end of the meeting. Though we may not be able to answer every question, we will do our best to provide a response to as many as possible. In keeping with the digital approach to this year's meeting, it is now 10:01 A.M. Eastern Time on July 13th, 2026, this meeting is officially called to order. Now I would like to introduce the other members of the Board of Directors present today. J. Michael Losh has served as one of our directors since February 2018. Gilbert S. Omenn, MD, PhD, has served as one of our directors since March 2020. Barbie Brewer has served as one of our directors since July 2019, George Parmer has served as one of our directors since November 2020. Now it is my pleasure to introduce Sean Reid of Sheppard, Mullin, Richter & Hampton LLP, the company's outside counsel, who will act as secretary of the meeting. I will turn to him with any procedural issues that may arise. Thanks, Ann Marie. We are also joined here today by the company's independent auditors. They will be available during the question and answer session after the meeting to respond to appropriate questions. Finally, the company has appointed Sarah Berman, Principal Financial and Accounting Officer of the company, to act as Inspector of Elections. Ms. Berman is with us today and has taken the oath of Inspector of Election. Now we commence the formal meeting. After the formal meeting has been adjourned, we will provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. Out of consideration for others, please limit yourself to one question. Please note that this meeting is being recorded. However, no one attending via the webcast or telephone is permitted to use any audio recording device. Now to the proof of notice of meeting and quorum. The board of directors fixed May 22, 2026, as the record date for determining stockholders entitled to vote at this meeting. An affidavit has been delivered attesting to the fact that either, one, a notice of internet availability of the notice of this meeting, the proxy statement, and the 2025 annual report to stockholders, or two, the documents themselves were mailed on or about June 3rd, 2026, to all stockholders as of the record date and will be incorporated into the minutes of this meeting. The stockholder list shows that as of the record date, there were 5,852,985 shares of common stock outstanding and entitled to vote at the meeting. We are informed by the Inspector of Election that there are represented in person or by proxy shares of common stock representing 2,321,797 votes, or approximately 39.66% of the voting power on the record date. Since this represents more than one-third of the voting power of all issued and outstanding stock entitled to vote on the record date, a quorum is present for the purposes of transacting business. Now I will present the matters to be voted upon. Please note that we give stockholders an opportunity to comment on the proposals themselves after all proposals have been presented. Proposal one is the election of 2 Class II directors to hold office for a full term of three years or until their successors are duly elected and qualified. Proposal two is the ratification of the appointment of Novogradac & Company LLP as the company's independent registered public accounting firm for the fiscal year ending June 30th, 2026. Proposal three is the approval of an amendment of the company's 2018 Equity Incentive Plan to, one, increase the number of shares available for issuance under the 2018 Equity Incentive Plan by 1 million shares, and two, increase the number of shares that may be issued pursuant to the exercise of incentive stock options by 1 million shares. Proposal four is the approval in accordance with Nasdaq Listing Rule 5635(d) of the issuance of an aggregate of 1,393,732 shares of common stock upon the exercise of the company's Series A warrants and the issuance of an aggregate of 1,393,732 shares of common stock upon the exercise of the company's Series A-2 warrants. If any stockholder would like to make a comment regarding any of the proposals, please submit your comment through the web portal. It is now 10:06 A.M. Eastern Time on July 13th, 2026, and the polls are now open. Any stockholder who hasn't yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their vote do not need to take any further action. Now we're pausing for voting, and I'll speak at intervals of a few seconds so that we prevent confusion if someone enters the meeting and hears no audio. We are paused for voting. Again, speaking at intervals to prevent confusion if someone were to enter the meeting and not hear video. We're paused for voting. Again, that is why you don't hear meeting transactions being discussed. All right. Now that everyone has had the opportunity to vote, I now declare the polls for the 2026 annual stockholder meeting closed. Turning it over to Sean. Thanks, Ann Marie. We have been informed by the Inspector of Elections that the preliminary vote report shows that the nominees for election to the board have been duly elected. The ratification of our independent registered public accounting firm has been approved. The amendment of the company's 2018 Equity Incentive Plan has been approved, and the issuance of shares of common stock on the exercise of the company's Series A-1 warrants and Series A-2 warrants has been approved. We will be reporting the final vote result in a Form 8-K to be filed within four business days. With that, I turn the meeting back over to Ann Marie. Thank you, Sean. There being no further business to come before the meeting, the annual meeting of stockholders of Amesite Inc. is now adjourned. Now I will give a brief presentation of Amesite's business, followed by our question and answer session. Briefly to update our stockholders, Amesite has had an exciting two years as we entered the healthcare space with a new product called NurseMagic. Originally entering the marketplace as a B2C product and then later quickly growing to B2B customers. We recently announced the win of a large census customer after a period of growth among our customer base and widening of our customer base to include several different care settings within the post-acute space, which is growing at the fastest CAGR of anything in the healthcare sector. We're pleased to be able to prove our ability to scale, and we are excited about future B2B growth. Now, we will take questions entered on the web portal. Please note that we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed. Any appropriate questions that we do not answer during the meeting will be addressed on our company website. Turning to shareholder questions. We have three today. First, where do you expect more growth, B2C or B2B, and why? Amesite anticipates greater growth B2B as we aim to become an AI layer for businesses that provide crucially important post-acute care in the United States. Once again, this sector is growing very, very fast, and they crucially need AI layers in order to become more efficient. The only answer to healthcare efficiency, of course, is innovation, and Amesite is very pleased to be doing that across multiple customers in the B2B space. Second, does Amesite view AI models as a strategic advantage, and which ones do you use right now and why? To answer that question, Amesite has, from its origin, believed that AI models will become scaled and more or less commoditized. Our value to our customer is being expert implementers of these models and being able to deploy the right model at the right time, whether it's an external commercially sourced model or whether it's something we build internally. That expertise is crucial to our customers being able to execute. Although it's clear that the power of AI models has transformed business and will continue to do so, there is real expertise required in selecting and deploying those models on secure, stable, scalable infrastructure, and that is what we do. We believe this places us in an enviable position in the marketplace because we're using our engineering and mathematics know-how, our business know-how to deploy solutions quickly for companies that need it critically in order to deliver excellent healthcare and also to remain competitive. Third question. Amesite, AMST, announced a large customer. Is that repeatable and why? We believe it's very repeatable. The reasons are threefold. First, we trained on B2C. We developed a product that had user acceptance and developed a loyal user base among nurses, who are the largest class of healthcare worker and the most important in the United States. By working B2C first, we proved our hypothesis correct that AI could be of benefit to the frontline healthcare worker at point of submission, particularly, and most importantly, at documentation. Documentation consumes roughly 40% of healthcare workers' time. It's not only important to have tools that are performant, meaning that the tools enable the user to submit documentation timely and to their standards, but also that they like to use. That's critically important. Having proven that, we believe we've proven that. Moving to B2B, we've showed that we could deliver scalable architectures that enabled many kinds of workers to access our technology. By allowing them to use our technology as an overlay to existing stacks, we believe we also have an enviable position in the marketplace, and that we don't have to make our customers rip and replace in order to access AI tools. This is critically important in this very large and very growing sector. Yes, we do believe strongly that this is repeatable because we did the reps, and we did the pieces of the technology to show how it works, not only at the ground level to users, but also at the scaled level. That being all of our questions, this concludes our meeting today. We do thank you for your attendance and continued support. Thank you, and have a great day. That concludes our meeting today. You may now disconnect.